Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

Needham Cuts Rigel Pharmaceuticals Rating to Hold from Buy

Needham cut its rating on Rigel Pharmaceuticals (RIGL) to hold from buy, explaining that the company's new allergy drug R112 failed to differ from placebos in clinical trials.

Analyst Mark Monane expects more information in a news conference today (at 4:30 pm Eastern Standard Time), as well as an update of the company's pending initiatives. He expects Rigel to halt its development of R112, but he continues to see the company developing potentially viable allergy drugs.

blog comments powered by Disqus